Three Texas plaintiffs and one Alabama defendant will find out in October from a panel of judges whether their federal testosterone replacement therapy lawsuits will be transferred to U.S. District Court for the Northern District of Illinois. Going on 200 federal cases are already there. Plaintiffs or their surviving next-of-kin claim testosterone replacement therapy led to serious injury, which proved fatal in some cases.
The U.S. Judicial Panel on Multidistrict Litigation summarized testosterone replacement therapy lawsuits this way in June: “All actions involve plaintiffs (or their survivors) who used one or more testosterone replacement therapies and contend that their (or their decedent’s) use of the drugs caused their injuries, which include heart attack, stroke, deep vein thrombosis, and pulmonary embolism.”
The litigation is fairly new and comes on the heels of the U.S. Food and Drug Administration’s ongoing scrutiny of testosterone replacement therapy.
Attorneys at the law firm of Reich & Binstock specialize in handling these types of drug injury lawsuits. Anyone who underwent testosterone replacement therapy and since has suffered heart attack, stroke or a blood clotting injury may want to talk to an attorney at Reich & Binstock, a law firm which has been fighting for 30 years for the rights of patients who were injured in the course of an unreasonably risky medical treatment.
At Reich & Binstock, the consultation is free. The firm, which operates in all 50 states, will charge nothing to examine the circumstances and determine whether there is an entitlement to compensation for injuries related to testosterone replacement therapy.
The injury claims have not come out of left field. These claims are backed by scientific study and an FDA investigation.
“FDA is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products,” according to the agency’s Jan. 31 safety alert. “We have been monitoring this risk and decided to reassess this safety issue based on the recent publication of two separate studies that each suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy.”
The FDA did not want to come to any conclusions about the nature of the health risks until its probe is complete. The agency also made a point about the patient-doctor relationship, writing, “Patients should not stop taking prescribed testosterone products without first discussing any questions or concerns with their health care professionals.”
Nevertheless, the injuries that have shown up in scientific studies also have shown up in litigation. If you think you have a case, consider consulting Reich & Binstock.
Reach Reich & Binstock either at 713-622-7271 or by sending an electronic message through the law firm’s website.